These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 38963839)
1. A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction. Ting PY; Borikar S; Kerrigan JR; Thomsen NM; Aghania E; Hinman AE; Reyes A; Pizzato N; Fodor BD; Wu F; Belew MS; Mao X; Wang J; Chitnis S; Niu W; Hachey A; Cobb JS; Savage NA; Burke A; Paulk J; Dovala D; Lin J; Clifton MC; Ornelas E; Ma X; Ware NF; Sanchez CC; Taraszka J; Terranova R; Knehr J; Altorfer M; Barnes SW; Beckwith REJ; Solomon JM; Dales NA; Patterson AW; Wagner J; Bouwmeester T; Dranoff G; Stevenson SC; Bradner JE Science; 2024 Jul; 385(6704):91-99. PubMed ID: 38963839 [TBL] [Abstract][Full Text] [Related]
2. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease. Lai ZS; Yeh TK; Chou YC; Hsu T; Lu CT; Kung FC; Hsieh MY; Lin CH; Chen CT; James Shen CK; Jiaang WT Eur J Med Chem; 2021 Jan; 209():112938. PubMed ID: 33109398 [TBL] [Abstract][Full Text] [Related]
3. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Green NS; Barral S Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494 [TBL] [Abstract][Full Text] [Related]
5. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology. Ito T; Yamaguchi Y; Handa H Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753 [TBL] [Abstract][Full Text] [Related]